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Figure S1: Study cohorts and objectives 
Abbreviations: CUP, Compassionate Use Program; IT, immunotherapy; CAR, chimeric antigen 
receptor; alloHCT, allogeneic hematopoietic cell transplantation; pola, polatuzumab vedotin; OR, 
overall response; CR, complete response; pola-R; polatuzumab vedotin-rituximab; pola-BR; 
polatuzumab vedotin-bendamustine-rituximab; PFS, Progression-free survival, OS, overall survival 
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Figure S2: Progression-free survival (A) and overall survival (B) in patients who either received a 
chemotherapy-containing or a chemotherapy-free polatuzumab vedotin-based treatment. Survival 
times were calculated from the initiation of pola treatment. 
Abbreviation: pola: polatuzumab vedotin, Pola-R, polatuzumab vedotin-rituximab; Pola(-R)-chemo, 
polatuzumab vedotin and chemotherapy +/- rituximab 
  
 
Figure S3: Landmark analysis from time of best response to polatuzumab vedotin (pola) treatment 
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